Ziconotide
As of the edition of 20 October 2026, Ziconotide is a protein: marketed, first approved in 2004 (US); acts on CACNA1B; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2005
- Kind
- Protein
- Brand name
- Prialt
- First approved
- 28 December 2004 (US)
- Approvals on record
- 5 in 2 regions
- Holder of the most recent approval
- Esteve Pharmaceuticals; 2 holders in all
- Registered trials
- 9, 1 stopped early
- Disease areas
- Cancer; Nervous system; Immune system; Blood and lymph; Infections; Injuries
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Ziconotide.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CACNA1B | Voltage-dependent N-type calcium channel subunit alpha-1B | Q00975 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 1 | 2 | 0 |
| Phase 2 | 2 | 1 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 3 | 2 | 0 | 1 |
| All trials | 9 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Elan Pharmaceuticals | Earlier holder | 2004 to now |
| Esteve Pharmaceuticals | Applicant and Acquired holder | 2005 to now |